Our work not only establishes CD2AP as a key prognostic biomarker and therapeutic target but also provides a compelling rationale for repurposing existing tyrosine kinase inhibitors to treat patients with LUAD and CD2AP-high tumours, ultimately offering a novel precision medicine strategy for this challenging disease. This evidence concerns the gene CD2AP and neoplasm.